Financial Performance Highlights
Q1 FY27 revenue stood at ₹257 crores, representing 26.2% year-on-year growth compared to ₹204 crores in Q1 FY26. The API segment contributed ₹219 crores (42% growth) while formulations contributed ₹39 crores (23% de-growth). Domestic revenue grew by 12% while export revenue showed strong growth of 46% year-on-year.
Gross margins for the quarter were 78.9%, an improvement of 100 basis points year-on-year, attributed to strong pricing discipline, favorable product mix, and limited competitive intensity. EBITDA reached ₹82 crores with 34% growth year-on-year, and EBITDA margins stood at 32% (190 bps improvement). PAT was ₹58 crores, growing 31% year-on-year with PAT margins of 22.4% (80 bps improvement).
The company maintained a zero-debt position with cash and cash equivalents of over ₹442 crores as of June 30, 2026. Capex for the quarter was approximately ₹9.5 crores.
Operational and Business Updates
Growth was broad-based across key product categories including immunosuppressants, anti-infectives, oncology, and antifungals. The company onboarded multiple new customers and engaged in advanced discussions with large customers for long-term product supplies.
Regulatory milestones included successful completion of ANVISA Brazil inspection for Limbasi facility, PPB Kenya and NDA Uganda approvals for Unit 2 formulation facility at Valthera. The company received ANDA approvals from US FDA for mycophenolate mofetil and Tofacitinib tablets.
Capacity Utilization and Facilities
Unit 1 capacity utilization was approximately 80%, Unit 3 at 55%, and Unit 2 at 25%. The injectable facility commenced commercial operations with current utilization around 5%. The company expects the injectable facility to contribute significantly to future revenue growth and margin expansion.
Growth Strategy and Outlook
Management expressed confidence in sustaining growth momentum based on business visibility and pipeline. The company targets 2-3 new product launches annually with several products at advanced development stages. Long-term vision includes achieving ₹3,000 crores revenue with ₹600-700 crores expected from formulations and balance from APIs, targeted over 5-6 years.
Stellon Biotech, the front-end distribution platform for formulation products in the US, commenced commercial operations though at nascent stage. CDMO business currently contributes 1-2% of revenue with target to reach double-digit contribution.
Sustainability Recognition
Concord Biotech was awarded a silver medal by EcoVadis for sustainability performance, placing it among top 15% of companies assessed globally.